BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Treatment
61 results:

  • 1. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
    Rajasekaran N; Wang X; Ravindranathan S; Chin DJ; Tseng SY; Klakamp SL; Widmann K; Kapoor VN; Vexler V; Keegan P; Yao S; LaVallee T; Khare SD
    Cancer Immunol Immunother; 2024 Feb; 73(3):60. PubMed ID: 38400933
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
    Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
    Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
    Xu X; Li Y; Xu R; Meng Y; Li Z; Zuo D; Wu Y
    FEBS J; 2024 Mar; 291(6):1199-1219. PubMed ID: 38148635
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. shp2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
    Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
    Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. RNA-Seq Analysis Reveals Altered Expression of Cell Adhesion-Related Genes Following PZR Knockout in lung cancer Cells.
    Fu Y; Li G; Fu X; Xing S; Zhao ZJ
    Appl Biochem Biotechnol; 2024 Apr; 196(4):2122-2136. PubMed ID: 37470934
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and shp2 inhibitors.
    Berry MA; Bland AR; Ashton JC
    Sci Rep; 2023 Jun; 13(1):10041. PubMed ID: 37339995
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. PI3K inhibition circumvents resistance to shp2 blockade in metastatic triple-negative breast cancer.
    Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M
    J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. shp2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
    Drilon A; Sharma MR; Johnson ML; Yap TA; Gadgeel S; Nepert D; Feng G; Reddy MB; Harney AS; Elsayed M; Cook AW; Wong CE; Hinklin RJ; Jiang Y; Brown EN; Neitzel NA; Laird ER; Wu WI; Singh A; Wei P; Ching KA; Gaudino JJ; Lee PA; Hartley DP; Rothenberg SM
    Cancer Discov; 2023 Aug; 13(8):1789-1801. PubMed ID: 37269335
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tumor Cell-Autonomous shp2 Contributes to Immune Suppression in Metastatic Breast cancer.
    Chen H; Cresswell GM; Libring S; Ayers MG; Miao J; Zhang ZY; Solorio L; Ratliff TL; Wendt MK
    Cancer Res Commun; 2022 Oct; 2(10):1104-1118. PubMed ID: 36969745
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
    Pan Y; Han H; Hu H; Wang H; Song Y; Hao Y; Tong X; Patel AS; Misirlioglu S; Tang S; Huang HY; Geng K; Chen T; Karatza A; Sherman F; Labbe KE; Yang F; Chafitz A; Peng C; Guo C; Moreira AL; Velcheti V; Lau SCM; Sui P; Chen H; Diehl JA; Rustgi AK; Bass AJ; Poirier JT; Zhang X; Ji H; Zhang H; Wong KK
    Cancer Cell; 2023 Jan; 41(1):88-105.e8. PubMed ID: 36525973
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell lung cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Ajuforrestin A, an Abietane Diterpenoid from
    Yan H; Jiang M; Yang F; Tang X; Lin M; Zhou C; Tan Y; Liu D
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080236
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in lung Adenocarcinoma Cells with an
    Nishihara S; Yamaoka T; Ishikawa F; Ohmori T; Ando K; Kusumoto S; Kishino Y; Manabe R; Hasebe Y; Sagara H; Yoshida H; Tsurutani J
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883645
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and shp2/Grb2 signaling pathways.
    Wang LN; Zhang ZT; Wang L; Wei HX; Zhang T; Zhang LM; Lin H; Zhang H; Wang SQ
    Cell Death Dis; 2022 May; 13(5):472. PubMed ID: 35589677
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Epithelial-to-mesenchymal transition hinders interferon-γ-dependent immunosurveillance in lung cancer cells.
    Tseng PC; Chen CL; Lee KY; Feng PH; Wang YC; Satria RD; Lin CF
    Cancer Lett; 2022 Jul; 539():215712. PubMed ID: 35490920
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.
    Ramdas B; Yuen LD; Palam LR; Patel R; Pasupuleti SK; Jideonwo V; Zhang J; Maguire C; Wong E; Kanumuri R; Zhang C; Sandusky G; Chan RJ; Zhang C; Stieglitz E; Haneline L; Kapur R
    Mol Ther; 2022 Jul; 30(7):2505-2521. PubMed ID: 35443935
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Hexachlorophene, a selective shp2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Knockdown of RNF183 suppressed proliferation of lung adenocarcinoma cells
    Ye G; Luo H; Zhang T; Lan T; Ling B; Qi Z
    Cell Cycle; 2022 May; 21(9):948-960. PubMed ID: 35104174
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.